A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Phase 1 Completed 72 enrolled Crucell Holland BV

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered as heterologous prime-boost vaccine regimens in healthy adult participants.

Timeline

Start: 2015-03
Primary completion: 2015-09
Completion: 2016-06

Publications

Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, Douoguih M. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. J Infect Dis. 2019 Jun 5;220(1):57-67. doi: 10.1093/infdis/jiz071.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN	Vaccine	0.5 ml	Intramuscular
Subject	ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN	Vaccine	5e+10 unknown	Intramuscular
Subject	MVA-BN-Filo	Vaccine	0.5 ml	Intramuscular
Subject	MVA-BN-Filo	Vaccine	1e+08 unknown	Intramuscular

Indications

No indication recorded.